Show simple item record

OVERVIEW AND PERSPECTIVES OF MESENCHYMAL STEM CELL THERAPY IN INTENSIVE CARE MEDICINE

Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva

dc.contributoren-US
dc.contributores-ES
dc.creatorEspinoza, Francisco; Universidad de los Andes. Avda Alvaro del Portillo 12455. Las Condes Santiago Chile
dc.creatorAliaga, Felipe; Hospital Militar de Santiago. Unidad de Cuidados Intensivos
dc.creatorCrawford, Patricia Luz; Institut de Recherche de Médecine Régénératrice et de Biothérapies
dc.date2016-01-21
dc.date.accessioned2019-11-11T18:26:30Z
dc.date.available2019-11-11T18:26:30Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4237
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110682
dc.descriptionDevelopment of innovative therapies in intensive care medicine is particularly important since diseases as sepsis, acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) have an elevated morbidity and mortality in spite of current gold-standard approaches. Mesenchymal stem cells (MSC) may have a promising role due to their properties in immunomodulation, tissue reparation and microbial clearance. Preclinical data and results of a systematic review of PubMed, PMC and ClinicalTrials.gov have been included to review the role of MSC therapy in sepsis, ARDS and AKI. A description of MSC biology, sources and benefits in preclinical models was included. A phase I/II clinical trial (RCT) is recruiting neutropenic patients with septic shock. In ARDS, the START trial (Stem cells in ARDS Treatment) is a phase I/II study of bone marrow-derived human MSC (hMSC) that is currently recruiting patients. In AKI, a phase I study has demonstrated the safety of hMSCs infusion in patients undergoing cardiac surgery with high risk to develop AKI. A phase II study is still active. The results of these studies will determine the real feasibility of MSC therapy in critically ill patients.en-US
dc.descriptionDevelopment of innovative therapies in intensive care medicine is particularly important since diseases as sepsis, acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) have an elevated morbidity and mortality in spite of current gold-standard approaches. Mesenchymal stem cells (MSC) may have a promising role due to their properties in immunomodulation, tissue reparation and microbial clearance. Preclinical data and results of a systematic review of PubMed, PMC and ClinicalTrials.gov have been included to review the role of MSC therapy in sepsis, ARDS and AKI. A description of MSC biology, sources and benefits in preclinical models was included. A phase I/II clinical trial (RCT) is recruiting neutropenic patients with septic shock. In ARDS, the START trial (Stem cells in ARDS Treatment) is a phase I/II study of bone marrow-derived human MSC (hMSC) that is currently recruiting patients. In AKI, a phase I study has demonstrated the safety of hMSCs infusion in patients undergoing cardiac surgery with high risk to develop AKI. A phase II study is still active. The results of these studies will determine the real feasibility of MSC therapy in critically ill patients.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4237/1834
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18316
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18317
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18318
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18319
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18320
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18321
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4237/18442
dc.sourceRevista Médica de Chile; Vol. 144, núm. 2 (2016): FEBRERO 2016es-ES
dc.source0034-9887
dc.subjectAcute Kidney Injury; Mesenchymal stromal cells; Respiratory Distress Syndrome, Adult; Sepsisen-US
dc.subjectAcute Kidney Injury; Mesenchymal stromal cells; Respiratory Distress Syndrome, Adult; Sepsises-ES
dc.titleOVERVIEW AND PERSPECTIVES OF MESENCHYMAL STEM CELL THERAPY IN INTENSIVE CARE MEDICINEen-US
dc.titleEscenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensivaes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record